产品号 #19842_C
免疫阴性选择试剂盒
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
概述
本产品旨在通过负选择从肺组织或其他组织的单细胞悬液中富集ILC2（2组先天淋巴样细胞）。利用生物素化抗体靶向非ilc2细胞和链亲和素包被磁颗粒（RapidSpheres™）去除不需要的细胞。使用EasySep™磁铁分离标记细胞，不使用色谱柱。
Magnet Compatibility
EasySep™ Magnet (Catalog #18000)
Subtype
Cell Isolation Kits
Cell Type
Innate Lymphoid Cells
Species
Mouse
Sample Source
Other
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep
Area of Interest
Immunology
Subtype
Cell Isolation Kits
Cell Type
Innate Lymphoid Cells
Species
Mouse
Sample Source
Other
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep
Area of Interest
Immunology
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Publications (2)
Isolation and adoptive transfer of innate lymphoid cells 2 to a recipient mouse model of PDAC. STAR protocols 2022 sep
Abstract
Innate lymphoid cells 2 (ILC2) play a significant role in the tumorigenesis of pancreatic ductal adenocarcinoma (PDAC). An important aspect of ILC2-mediated tumorigenesis is the expansion of the resident ILC2 and simultaneous recruitment of the peripheral ILC2. Here, we describe a protocol for isolation, enrichment, and DiD labeling of ILC2 for in vivo tracking of ILC2s in the mouse. Further, we describe steps for the adoptive transfer of ILC2 to a recipient mouse model of PDAC. For complete details on the use and execution of this protocol, please refer to Alam et al. (2022).
IL-33 induces NF-$\kappa$B activation in ILC2 that can be suppressed by in vivo and ex vivo 17$\beta$-estradiol. Frontiers in allergy 2022
Abstract
Asthmatic women tend to develop severe airway disease in their reproductive years, and 30%-40% of asthmatic women have peri-menstrual worsening of asthma symptoms. This indicates that fluctuations in ovarian hormones are involved in advancement of asthmatic disease and exacerbation of symptoms. Group 2 innate lymphoid cells, or ILC2, are readily detected in allergic conditions, such as rhinosinusitis, in individuals that develop nasal polyps do to allergen exposures, and in allergic asthma. ILC2 are airway localized immune cells activated by IL-33, an innate cytokine that perpetuates allergic inflammation by driving the production of IL-5 and IL-13. We have previously shown that ILC2 are highly activated in na{\{i}}ve and ovalbumin (OVA) challenged female BALB/c mice in comparison to male mice following stimulation with IL-33. Here we investigated the effect of steady-state ovarian hormones on ILC2 and the NF-$\kappa$B signaling pathway following OVA sensitization and challenge. We found that estrogen-treated ovariectomized mice (OVX-E2) that had been challenged with OVA had reduced IL-5 and IL-13 production by lung ILC2 as compared to lung ILC2 isolated from intact male and female sham-operated controls that had been treated with OVA. ILC2 were isolated from untreated animals and co-cultured ex vivo with and without estrogen plus IL-33. Those estrogen-treated ILC2 similarly produced less IL-5 and IL-13 in comparison to untreated and had reduced NF-$\kappa$B activation. Single-cell RNA sequencing showed that 120 genes were differentially expressed in male and female ILC2 and Nfkb1 was found among top-ranked regulatory interactions. Together these results provide new insight into the suppressive effect of estrogen on ILC2 which may be protective in female asthmatics. Understanding further how estrogen modulates ILC2 may provide therapeutic targets for the treatment of allergic diseases."
更多信息
| Species | Mouse |
|---|---|
| Magnet Compatibility | EasySep™ Magnet (Catalog #18000) |
| Sample Source | Other |
| Selection Method | Negative |
标记抗体
-
抗小鼠CD19抗体，克隆1D3抗小鼠CD19的大鼠单克隆IgG2a抗体
-
抗小鼠CD45抗体，克隆30-F11抗小鼠CD45大鼠单克隆IgG2b抗体
-
抗小鼠NK1.1 （CD161）抗体，克隆PK136（C3H x BALB/c） F1杂交单克隆抗小鼠NK1.1 （CD161）抗体
-
抗小鼠TER119抗体，克隆TER-119抗小鼠TER119的大鼠（WI）单克隆IgG2b抗体
-
抗小鼠CD11c抗体，克隆N418亚美尼亚仓鼠抗小鼠CD11c单克隆IgG抗体
-
抗小鼠CD3e抗体，克隆145-2C11亚美尼亚仓鼠抗小鼠CD3e单克隆IgG1抗体
-
抗小鼠Gr-1抗体，克隆RB6-8C5抗小鼠Gr-1 （Ly-6G/Ly-6C）大鼠单克隆IgG2b抗体
-
抗小鼠TCR γ / δ抗体，克隆GL3亚美尼亚仓鼠抗小鼠T细胞受体γ / δ单克隆IgG2抗体
-
抗小鼠CD11b抗体，克隆M1/70抗人、小鼠、恒河猴CD11b的大鼠单克隆IgG2b抗体
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
